Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females

References

• El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2015;21(25):7621–7636. doi: 10.3748/wjg.v21.i25.7621.
   PubMed Web of Science ®Google Scholar
• Wilson BC, Vatanen T, Cutfield WS, et al. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:2. doi: 10.3389/fcimb.2019.00002.
   PubMed Web of Science ®Google Scholar
• Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623–628. doi: 10.1038/nature25979.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2018;12(5):439–445. doi: 10.1080/17474124.2018.1447380.
   PubMed Web of Science ®Google Scholar
• Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71–83. doi: 10.1111/apt.13236.
   PubMed Web of Science ®Google Scholar
• Enck P, Mazurak N. Dysbiosis in functional bowel disorders. Ann Nutr Metab. 2018;72(4):296–306. doi: 10.1159/000488773.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Hausken T. Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hausken T, Hatlebakk JG. Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(11):e14157. doi: 10.1111/nmo.14157.
   PubMed Web of Science ®Google Scholar
• Jamshidi P, Farsi Y, Nariman Z, et al. Fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Mol Sci. 2023;24(19):14562. doi: 10.3390/ijms241914562.
   PubMed Web of Science ®Google Scholar
• Mohan BP, Loganathan P, Khan SR, et al. Fecal microbiota transplant delivered via invasive routes in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2023;42(3):315–323. doi: 10.1007/s12664-023-01373-5.
   PubMed Web of Science ®Google Scholar
• Halkjær SI, Lo B, Cold F, et al. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. World J Gastroenterol. 2023;29(20):3185–3202. doi: 10.3748/wjg.v29.i20.3185.
   PubMed Web of Science ®Google Scholar
• Wang M, Xie X, Zhao S, et al. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023;14:1136343. doi: 10.3389/fimmu.2023.1136343.
   PubMed Web of Science ®Google Scholar
• Rodrigues T, Rodrigues Fialho S, Araújo JR, et al. Procedures in fecal microbiota transplantation for treating irritable bowel syndrome: systematic review and meta-analysis. J Clin Med. 2023;12(5):1725. doi: 10.3390/jcm12051725.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Hold GL. A systematic review, pairwise meta-analysis and network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2023;35(4):471–479. doi: 10.1097/MEG.0000000000002519.
   PubMed Web of Science ®Google Scholar
• Samuthpongtorn C, Kantagowit P, Pittayanon R, et al. Fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2022;9:1039284. doi: 10.3389/fmed.2022.1039284.
   PubMedGoogle Scholar
• Abdelghafar YA, AbdelQadir YH, Motawea KR, et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: an update based on meta-analysis of randomized control trials. Health Sci Rep. 2022;5(5):e814.
   PubMedGoogle Scholar
• Zhao HJ, Zhang XJ, Zhang NN, et al. Fecal microbiota transplantation for patients with irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Nutr. 2022;9:890357. doi: 10.3389/fnut.2022.890357.
   PubMedGoogle Scholar
• Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022;12:827395. doi: 10.3389/fcimb.2022.827395.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859–867. doi: 10.1136/gutjnl-2019-319630.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Kristoffersen AB, Valeur J, et al. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2021;34(1):e14200.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Winkel R, Casen C, et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982–994.e914. doi: 10.1053/j.gastro.2022.06.020.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Hatlebakk JG. Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome. Neurogastroenterol Motil. 2023;e14641. doi: 10.1111/nmo.14641.
   PubMed Web of Science ®Google Scholar
• Papanicolas LE, Choo JM, Wang Y, et al. Bacterial viability in faecal transplants: which bacteria survive? EBioMedicine. 2019;41:509–516. doi: 10.1016/j.ebiom.2019.02.023.
   PubMed Web of Science ®Google Scholar
• Widjaja F, Rietjens I. From-toilet-to-freezer: a review on requirements for an automatic protocol to collect and store human fecal samples for research purposes. Biomedicines. 2023;11(10):2658. doi: 10.3390/biomedicines11102658.
   PubMed Web of Science ®Google Scholar
• Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol. 2010;25(4):691–699. doi: 10.1111/j.1440-1746.2009.06120.x.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Casen C, Valeur J, et al. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World J Gastroenterol. 2021;27(18):2219–2237. doi: 10.3748/wjg.v27.i18.2219.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145–157.e148. doi: 10.1053/j.gastro.2020.07.013.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hausken T, Hatlebakk JG. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS). Nutrients. 2019;11(6):1415. doi: 10.3390/nu11061415.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95(4):999–1007. doi: 10.1111/j.1572-0241.2000.01941.x.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108–2131. doi: 10.1053/gast.2002.37095.
   PubMed Web of Science ®Google Scholar
• Wong RK, Drossman DA. Quality of life measures in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010;4(3):277–284. doi: 10.1586/egh.10.19.
   PubMed Web of Science ®Google Scholar
• Arslan G, Lind R, Olafsson S, et al. Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the nepean dyspepsia index. Dig Dis Sci. 2004;49(4):680–687. doi: 10.1023/b:ddas.0000026318.81635.3b.
   PubMed Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
   PubMed Web of Science ®Google Scholar
• Roalfe AK, Roberts LM, Wilson S. Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol. 2008;8(1):30. doi: 10.1186/1471-230X-8-30.
   PubMedGoogle Scholar
• Hendriks C, Drent M, Elfferich M, et al. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018;24(5):495–503. doi: 10.1097/MCP.0000000000000496.
   PubMed Web of Science ®Google Scholar
• Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51–58. doi: 10.1111/jgh.12727.
   PubMed Web of Science ®Google Scholar
• Santos-Marcos JA, Haro C, Vega-Rojas A, et al. Sex differences in the gut microbiota as potential determinants of gender predisposition to disease. Mol Nutr Food Res. 2019;63(7):e1800870.
   PubMed Web of Science ®Google Scholar
• Parker BJ, Wearsch PA, Veloo ACM, et al. The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906. doi: 10.3389/fimmu.2020.00906.
   PubMed Web of Science ®Google Scholar
• Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–995. doi: 10.1016/j.clinthera.2015.04.002.
   PubMed Web of Science ®Google Scholar
• Rautio M, Eerola E, Väisänen-Tunkelrott ML, et al. Reclassification of bacteroides putredinis (Weinberg et al., 1937) in a new genus alistipes gen. nov., as Alistipes putredinis comb. nov., and description of Alistipes finegoldii sp. nov., from human sources. Syst Appl Microbiol. 2003;26(2):182–188. doi: 10.1078/072320203322346029.
   PubMed Web of Science ®Google Scholar
• Mishra AK, Gimenez G, Lagier JC, et al. Genome sequence and description of alistipes senegalensis sp. nov. Stand Genomic Sci. 2012;7(1):1–11. doi: 10.4056/sigs.2956294.
   PubMed Web of Science ®Google Scholar
• Mavromatis K, Stackebrandt E, Munk C, et al. Complete genome sequence of the bile-resistant pigment-producing anaerobe Alistipes finegoldii type strain (AHN2437(T)). Stand Genomic Sci. 2013;8(1):26–36. doi: 10.4056/sigs.3527032.
   PubMed Web of Science ®Google Scholar
• Urdaneta V, Casadesús J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med. 2017;4:163. doi: 10.3389/fmed.2017.00163.
   PubMed Web of Science ®Google Scholar
• Stasi C, Bellini M, Bassotti G, et al. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol. 2014;18(7):613–621. doi: 10.1007/s10151-013-1106-8.
   PubMed Web of Science ®Google Scholar
• Fuentes IM, Christianson JA. Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil. 2016;28(11):1613–1618. doi: 10.1111/nmo.12979.
   PubMed Web of Science ®Google Scholar
• Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19(1 Suppl):62–88. doi: 10.1111/j.1365-2982.2006.00875.x.
   PubMedGoogle Scholar
• Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7(1):91. doi: 10.1186/s40168-019-0704-8.
   PubMed Web of Science ®Google Scholar
• MacFabe DF, Cain NE, Boon F, et al. Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav Brain Res. 2011;217(1):47–54. doi: 10.1016/j.bbr.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Christopherson MR, Dawson JA, Stevenson DM, et al. Unique aspects of fiber degradation by the ruminal ethanologen Ruminococcus albus 7 revealed by physiological and transcriptomic analysis. BMC Genomics. 2014;15(1):1066. doi: 10.1186/1471-2164-15-1066.
   PubMedGoogle Scholar
• Ze X, Duncan SH, Louis P, et al. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. Isme J. 2012;6(8):1535–1543. doi: 10.1038/ismej.2012.4.
   PubMed Web of Science ®Google Scholar
• Hall AB, Yassour M, Sauk J, et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017;9(1):103. doi: 10.1186/s13073-017-0490-5.
   PubMedGoogle Scholar
• Ostojic SM. Inadequate production of H(2) by gut microbiota and parkinson disease. Trends Endocrinol Metab. 2018;29(5):286–288. doi: 10.1016/j.tem.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Zagato E, Pozzi C, Bertocchi A, et al. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol. 2020;5(3):511–524. doi: 10.1038/s41564-019-0649-5.
   PubMed Web of Science ®Google Scholar
• Pujo J, Petitfils C, Le Faouder P, et al. Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis. Gut. 2021;70(6):1088–1097. doi: 10.1136/gutjnl-2020-321173.
   PubMed Web of Science ®Google Scholar